New insights in Formyl-peptide Receptors functions by Parisi, Melania
  
 
 
 
 
UNIVERSITA’ DI NAPOLI FEDERICO II 
 
DOTTORATO DI RICERCA IN BIOCHIMICA 
E BIOLOGIA CELLULARE E MOLECOLARE 
XXVIII CICLO 
 
 
Melania Parisi 
 
 
New insights in Formyl-peptide Receptors functions 
 
 
 
 
Anno accademico 2014/2015 
  
  
 
UNIVERSITA’ DI NAPOLI FEDERICO II 
 
DOTTORATO DI RICERCA 
BIOCHIMICA E BIOLOGIA CELLULARE E MOLECOLARE 
XXVIII CICLO 
 
 
 
 
New insights in Formyl-peptide Receptors functions 
 
 
 
 
Melania Parisi 
 
 
 
 
 
Relatore Coordinatore 
Prof. Rosario Ammendola Prof. Paolo Arcari 
 
 
 
 
 
Anno Accademico 2014/2015 
 
 Ringraziamenti e dediche 
 
Un altro percorso importante è giunto a termine. Un percorso ricco di 
sacrifici, passione e tante soddisfazioni. Un ringraziamento particolare 
va anzitutto al Prof. Rosario Ammendola, il primo ad aver creduto in 
me. Grazie per avermi guidato con saggi consigli e avermi trasmesso 
la sua esperienza professionale ed umana. La sua tenacia, 
accompagnata dalla sua ironia e dolcezza, mi ha sostenuta anche nei 
momenti più difficili. Ringrazio la Prof.ssa Giulia Russo per i preziosi 
suggerimenti per il miglioramento del presente lavoro. Un grazie 
speciale al Dott. Fabio Cattaneo che ha sempre creduto nelle mie 
capacità, grazie  per avemi trasmesso la passione per la  ricerca e di 
essere sempre stato presente. Vorrei esprime la mia gratitudine ai miei 
amici e colleghi di lavoro Dott.ssa Ilenia Agliarulo, Dott.ssa Maria 
Rosaria, Dott. Swann Danilo Matassa, Dott. Rosario Avolio e la 
Dott.ssa Diana Arzeni che non hanno mai smesso di supportami e 
sopportarmi e di non avermi mai lasciata sola. La vostra amicizia è 
stata un tesoro scoperto per caso in questa non facile avventura e 
senza la quale questo dottorato non sarebbe mai stato altrettanto 
prezioso. 
Non posso dimenticare l’immenso debito di gratitudine verso i miei 
genitori e mio fratello che  hanno sostenuto le scelte personali e 
professionali più importanti della mia vita e non hanno mai mancato 
di incondizionato amore, ascolto e attenzione. Grazie a Salvatore, il 
mio futuro marito, che è sempre stato al mio fianco e con grande 
amore mi ha sostenuta durante tutto il percorso. Grazie alla mia amica 
speciale, Maria Rosaria, per essermi sempre accanto nei momenti di 
gioia ma anche in quelli più duri. Grazie a tutte le persone che non ho 
menzionato ma che riservano un posto speciale nel mio cuore. 
Grazie a te angelo mio per essere sempre con me. 
 
 
“Non permettere mai a nessuno di dirti che non sai fare qualcosa. 
Se hai un sogno tu lo devi proteggere. Se vuoi qualcosa, vai ed 
inseguila.” 
 
Melania 
 
Riassunto 
 
La famiglia dei recettori accoppiati a proteine G (GPCR) comprende 
la maggior parte dei recettori noti, in grado di convertire un’ampia 
varietà di stimoli extracellulari in risposte intracellulari attraverso 
l’attivazione delle proteine G eterotrimeriche, costituendone una 
categoria importante. Per il loro coinvolgimento in diversi processi 
fisiologici e patologici rappresentano target ideali per lo sviluppo di 
nuovi agenti terapeutici. Il recettore per N-formil peptidi FPR1 e le 
sue varianti FPR2 e FPR3 appartengono alla famiglia dei recettori a 
sette tratti trans-membrana accoppiati a proteina Gi, sensibili 
all’azione della tossina della pertosse (PTX). La loro espressione è 
stata individuata inizialmente in cellule del compartimento 
polimorfonucleato dove tali recettori mediano la migrazione dei 
fagociti presso i siti di infezione batterica e/o di danno tissutale, 
contribuendo alla risposta umorale innata. I recettori accoppiati a 
proteina G sono in grado di transattivare i recettori tirosina kinasi 
presenti sulla membrana cellulare. Questo meccanismo di cross-talk 
tra differenti sistemi di signaling gioca un ruolo chiave nel coordinare 
la pletora di stimoli extracellulari ai quali la cellula è sottoposta in 
condizioni fisio-patologiche. Abbiamo analizzato la capacità di FPR2 
di transattivare il recettore per il fattore di crescita epatico (c-Met) in 
cellule epiteliali di prostata (PNT1A) e di FPR1 di tranattivare il 
recettore per il fattore di crescita dell’endotelio vascolare (VEGFR2) 
in cellule endoteliali (ECV). I risultati hanno mostrato che 
WKYMVm, agonista di FPR2 induce la fosforilazone delle tirosine 
1313, 1349 e 1356 di c-Met e N-fMLP agonista di FPR1 determina la 
fosforilazione del residuo di tirosina 996 di VEGFR2. Come risultato 
della transattivazione, le tirosine fosforilate di questi due recettori 
forniscono sito di attracco per il reclutamento di molecole trasduttori 
di segnale evocando l’attivazione di STAT3, PLC-γ/PKCα e del 
pathway PI3K/AKT. La generazione di specie reattive dell’ossigeno 
da parte della NADPH ossidasi gioca un ruolo chiave in questo 
meccanismo di cross-talk, infatti, agenti in grado di bloccare l’attività 
della NADPH ossidasi prevengono la trasattivazione dei due recettori 
tirosina kinasi nonché i meccanismi molecolari a valle.  
Modelli correnti indicano che ciascun GPCR ed il set di proteine 
eterotrimeriche ad essi associate sulla superficie cellulare innescano 
una o più vie di segnalazione intracellulare attraverso complessi di 
GTPasi, chinasi e proteine ad essi legati. Recenti studi di “trafficking” 
di alcuni GPCRs hanno mostrato, che in seguito a stimolazione con 
specifici ligandi o ad attivazione attraverso meccanismi ligando-
indipendente, i GPCRs possono essere esposti sulla membrana 
nucleare per periodi prolungati, ed  innescare eventi di segnalazione 
diversi ed in alcuni casi opposti rispetto a quelli mediati dai GPCR di 
membrana. Abbiamo dimostrato mediante esperimenti di western blot, 
immonofluoscenza e saggi di binding che l’isoforma FPR2, ma non 
FPR1 ed FPR3, è espressa sulla membrana nucleare di cellule di 
cancro anaplastico del polmone (Calu6) e di adenocarcinoma gastrico 
(AGS). FPR2 nucleare è un recettore funzionale, in quanto partecipa 
al signaling intra-nucleare, come dimostrato dalla diminuzione della 
proteina Gi associata al recettore, dalla fosorilazione di ERK2, c-Jun e 
c-Myc, in seguito a stimolazione di nuclei intatti con WKYMVm, 
agonista selettivo di FPR2. Abbiamo quindi ipotizzato che la sequenza 
amminoacidica di FPR2 potesse contenere una sequenza di 
localizzazione nucleare (NLS) che giustificasse la sua 
dislocazionesulla membrane nucleare. Attraverso analisi bio-
informatiche in silico ed un programma di predizione di sequenze 
contenenti NLS, abbiamo identificato la sequenza (227-KIHKK-231) 
presente nel terzo loop intracellulare del recettore, costituita da 
amminoacidi basici (lisina, isoleucina, istidina, lisina, lisina). Sono 
stati condotti quindi esperimenti di mutagenesi sito-diretta della 
putativa NLS.  La sequenza consenso è stata mutata e il  cDNA è  
stato trasfettato in cellule HEK293, che non esprimono il recettore 
FPR2. L'amminoacido basico lisina, che segue l’istidina, nella 
sequenza -KIHKK- è stato mutato in alanina (apolare e idrofobico), 
originando la sequenza -KIHAK- (FPR2 mut 3). A partire da tale 
mutante ulteriori mutazioni sono state effettuate a carico dell’istidina e 
dell’ultima lisina generando il mutante -KIAAA- (FPR2 mut bis), 
dove due alanine hanno sostituito i due amminoacidi basici. 
Esperimenti di immunofluorescenza e western blot hanno mostrato 
che la localizzazione o traslocazione nucleare di FPR2 dipende 
dall’integrità dell’istidina 229 e dalla lisina 231. 
Questi risultati evidenziano un ruolo inaspettato dei recettori FPRs, 
sottolineando che per la loro promiscuità e il legame a diversi ligandi, 
unita alla loro espressione in differenti tipi cellulari e tessuti,  tali 
recettori possono avere  funzioni diverse in contesti biologi differenti. 
Una migliore comprensione dei meccanismi molecolari potrebbe 
portare all’identificazione di targets terapeutici per lo sviluppo di 
nuovi farmaci. 
 
Summary 
 
GPCRs (G-protein-coupled receptors) are versatile signaling 
molecules at the cell surface and are the largest and most diverse 
family of membrane receptors in the human genome. They convert a 
large variety of extracellular stimuliinto intracellular response through 
the activation of heterotrimeric G-proteins, which constitute the key 
regulatory elements in a broad range of normal and pathological 
processes and the most important targets for pharmaceutical drug 
discovery. The human formyl-peptide receptor FPR1 and its variants 
FPR2 and FPR3 belong to the Gi-protein coupled seven 
transmembrane receptor family sensitive to pertussis toxin (PTX)as 
indicated by the total loss of cell response to their agonists upon 
exposure to pertussis toxin.They are expressed in several cell types 
and their crucial biological functions are supported by the 
identification of high affinity host-derived agonists. An important 
feature of GPCR is their ability to transactive tyrosine kinase receptor. 
This cross-communication between different signaling systems plays a 
key role to coordinate the plethora of extracellular stimuli to which a 
cell is subjected under several physiological or pathological 
conditions. We investigated the ability of FPR2 to transactivate the 
RTK Hepatocyte growth factor receptor (c-Met) in PNT1A cells and 
of FPR1 to cross-talk with the vascular endothelial growth factor 
receptor (VEGFR) in ECV cells. We show that WKYMVm an FPR2 
agonist  induces the phosphorylation of  Y1313/1349/1356 of c-Met 
and the FPR1 agonist N-fMLP  triggers VEGFR2 activation by 
phosphorilation of Y996 residue.As a result of transactivation, 
phosphotyrosine residues of two receptors provide docking sites for 
recruitment and triggering of STAT3, PLC-γ/PKCα and PI3K/Akt 
pathways in both cell lines. The critical role of NADPH oxidase-
dependent superoxide generation in this cross-talk mechanism is 
supported by the finding that blockade of NADPH oxidase function 
prevents trans-phosphorylation of two TRKs and the resulting 
downstream signalling cascade. 
Current model indicate that each GPCR and associated sets of 
heterotrimeric G proteins on the cell surface had been proven to 
initiate one or more chains of intracellular signaling events mediated 
by complexes of GTPases, kinases, and linking proteins.Recentstudies 
of intracellular trafficking of a few different GPCRs, evoked by 
exposure to ligand or by cellular activation through ligand-
independent mechanisms, have shown that GPCRs may be inserted 
into nuclear membranes for prolonged periods, compose distinctive 
signaling units there, and respond to specific intracellular ligand by 
transducing nuclear transcriptional signals that differ from those sent 
by their plasma membrane complexes.We show by western blot 
analysis, immunofluorescence experiments and radioligand binding 
assays that FPR2, but not FPR1 and FPR3, is expressed at nuclear 
level in CaLu-6 and AGS cells. Nuclear FPR2 is a functional receptor, 
since it participates in intra-nuclear signaling, as assessed by 
decreased G protein-FPR2 association and enhanced ERK2, c-Jun and 
c-Myc phosphorylation upon stimulation of intact nuclei with the 
FPR2 agonist, WKYMVm. We analyzed FPR2 sequence for the 
search of a nuclear localization sequence (NLS) and we found a 
stretch of basic aminoacids (227-KIHKK-231) in the third 
cytoplasmic loop of the receptor. We performed single (K230A) and 
multiple (H229A/K230A/K231A) mutagenesis of NLS. The 
constructs were individually overexpressed in HEK293 cells and 
immunofluorescence and western blot analysis showed that nuclear 
localization or translocation of FPR2 depends on the integrity of the 
H229 and K231 residues within the NLS. 
Taken together, our data indicate that FPRs play new unexepected 
roles in cell signaling and function. The promiscuity of these receptors 
in binding different ligands, coupled with their presence in different 
cells and tissues, indicates a diverse role in multiple biological 
settings. A better understanding of these fundamental functions could 
lead to the identification of new therapeutic targets for drug 
development. 
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1. Introduction 
1.1. Structure and function of G-protein-coupled-receptor 
GPCRs (G-protein-coupled receptors) are versatile signaling 
molecules at the cell surface and constitute the largest and most 
diverse family of membrane receptors in the human genome. They 
convert a large variety of extracellular stimuli into intracellular 
response through the activation of heterotrimeric G-proteins. GPCRs 
represent key regulatory elements in a broad range of normal and 
pathological processes as well as the most important targets for 
pharmaceutical drug discovery [1].They share a common seven-
transmembrane (7TM) topology. Diversity of the extracellular ligands 
is reflected in the structural diversity of more than 800 human GPCRs, 
which can be grouped in families and numerous subfamilies on the 
basis of their aminoacid sequences [2]. Variations in extracellular 
loops, TM helices, and side chains create a remarkable variety of 
sizes, shapes, and electrostatic properties of the ligand binding pockets 
in different GPCR subfamilies, reflecting the diversity of their 
corresponding ligands [2]. G proteins, form hetero-trimers composed 
of Gα, Gβ and Gγ subunits. G protein α subunits, possess an intrinsic 
GTPase activity, which enables them to act as time switches: 
hydrolysis of the bound GTP to GDP promotes the re-association of 
the α subunit with the βγ dimer and renders the G protein in an 
inactive form [3]. Gα subunits are grouped into four families on the 
basis of their amino acid similarity and function. These include, Gαs 
and Gαi/o which stimulate or inhibit an adenylate cyclase, 
respectively, Gαq/11 which stimulates a phospholipase C, and the less 
characterized Gα12/13 family that activates the Na+/H+ exchanger 
pathway [4]. GPCRs interact specifically with the α subunits of the G 
proteins through their intracellular domains, however the same G 
protein may be activated by several receptors and the same receptor 
may couple to different G proteins, under different circumstances [4]. 
GPCR activity represents a coordinated balance between molecular 
mechanisms governing receptor signaling, desensitization, and 
resensitization. The desensitization is the consequence of a 
combination of different mechanisms. These mechanisms include the 
uncoupling of the receptor from heterotrimeric G proteins in response 
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to receptor phosphorylation [5], the internalization of cell surface 
receptors to intracellular membranous compartments, and the 
downregulation of the total cellular complement of receptors due to 
reduced receptor mRNA and protein synthesis, as well as both the 
lysosomal and plasma membrane degradation of pre-existing receptors 
[5]. The extent of receptor desensitization varies from complete 
termination of signaling, to the attenuation of agonist potency and 
maximal responsiveness. Three families of regulatory molecules are 
known to contribute to the GPCR desensitization process: second 
messenger-dependent protein kinases, G protein-coupled receptor 
kinases (GRKs) and arrestins [6]. The most rapid means by which 
GPCRs are uncoupled from heterotrimeric G proteins is through the 
covalent modification of the receptor as a consequence of 
phosphorylation by intracellular kinases. The GRK family of kinases 
is comprised of seven family members (GRK1-GRK7) that share 
significant sequence homology. GRK family members selectively 
phosphorylate agonist activated receptors, thereby promoting the 
binding of cytosolic cofactor proteins called arrestins, which sterically 
uncouple the receptor from heterotrimeric G protein [7]. GRKs 
phosphorylate GPCRs at both serine and threonine residues localized 
within either the third intracellular loop or carboxyl-terminal tail 
domains. The relative contributions and mechanisms by which second 
messenger-dependent protein kinases and GRKs regulate GPCR 
desensitization are not fully understood. Beta-arrestin is a small 
protein that can regulate GPCRs desensitization and internalization 
[8]. An other important aspect of GPCR desensibilization is the 
internalization or sequestration of agonist-activated receptors into the 
intracellular membrane compartments of the cell. Different receptor 
types utilize distinct pathways for removal from the cell surface, such 
as clathrin-coated pits or caveolae-mediated endocytosis. Once 
internalized, receptors traffic in intracellular vesicles through a series 
of intracellular vesicular compartments that eventually lead to release 
of the receptor back onto the cell surface in an activatable state [9]. 
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1.2. N-formil peptide receptors 
The human formyl-peptide receptor FPR1 and its variants 
FPR2 and FPR3 belong to the Gi-protein coupled seven 
transmembrane receptor family sensitive to pertussis toxin [10], as 
indicated by the total loss of cell response to their agonists upon 
exposure to pertussis toxin (PTX). Pertussis toxin catalyses an ADP-
ribosylation of Gα, arresting Gα in the GDP-bound state and, in turn,  
prevents the protein to transduce signals [10]. In human three genes 
encoding two functional receptors, FPR1and FPR2, and the putative 
receptor FPR3 have been identified. Human FPR1 was first defined 
biochemically, in 1976, as a high affinity binding site on the surface 
of neutrophils for the prototypic N-formyl peptide formyl-methionine-
leucyl-phenylalanine (fMLP). It was then cloned in 1990, from a 
differentiated HL-60 myeloid leukemia-cell cDNA library [11]. 
Functionally, FPR1 is activated by picomolar to low nanomolar 
concentrations of fMLP, and is therefore also identified as the high-
affinity fMLP receptor. It is encoded by a 6 kb single copy gene [12], 
the open reading frame is intronless but the 5% untranslated region 
resides in three exons. The start sites for transcription and translation 
are separated by approximately 5 kb. The proposed promoter contains 
a nonconsensus TATA box and an inverted CCAAT element. FPR1  
is a 350-residue protein with seven hydrophobic segments [12]. A 
subsequent study characterized FPR1 as a seven-transmembrane 
receptor with the N-terminus and three loops exposed on the cell 
surface for ligand interactions and the C-terminus and the remaining 
loops found within the cytoplasm necessary for intracellular signaling 
[13]. FPR1 expression has initially been described in phagocytic 
leukocytes, monocytes and neutrophils. It was later observed in 
immature dendritic cells (DCs), microglial cells, platelets, spleen and 
bone marrow. It is also described in non-hematopoietic cell 
populations and tissues, such as hepatocytes, fibroblasts, astrocytes, 
neurons of the autonomic nervous system, lung and lung carcinoma 
cells, thyroid, adrenals, heart, the tunica media of coronary arteries, 
uterus, ovary, placenta, kidney, stomach and colon. Using low-
stringency hybridization with FPR1 cDNA as the probe, two separate 
but relatively conserved low-affinity receptors, were cloned from 
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amRNA library of neutrophil-like promyelocytic HL-60 cells. These 
receptors have been named FPR2/ALX and FPR3, respectively, as 
more has become known about their distinct biochemical and 
physiological roles. All three receptors are clustered together on 
chromosome 19q13.3 and share significant sequence homology [14]. 
The sequence similarity between FPR1 and FPR2 is 69% at the 
aminoacid level. Although there is a large sequence similarity also 
between FPR2 and FPR3 (83% identity at the aminoacid level) [15] 
the latter can not bind formylated peptides. The similarities between 
the receptors are even larger when only the intracellular signalling 
transducing domains are compared [15]. FPR2 is considered a low-
affinity fMLP receptor based on observations that high concentrations 
of fMLP could elicit only Ca2+ mobilization but not chemotaxis 
through this receptor and compared to FPR1. FPR2 is also expressed 
in a large variety of cells and organs, including monocytes, 
macrophages, neutrophils, T and B lymphocytes, microglial cells, 
platelets, hepatocytes, epithelial cells, microvascular endothelial cells, 
fibroblasts, spleen, lung, testis, placenta, brain and bone marrow, as 
well as astrocytoma and neuroblastoma cells [16]. FPR3 transcripts 
were detected in a wide variety of tissues, including spleen, 
lymphnodes, lung, trachea, liver, adrenal gland, small intestine, 
placenta, and other tissues at lower levels. FPR3 is the only receptor 
expressed by both immature and mature dendritic cells. 
Classic studies suggested that the N-formyl group was a crucial 
determinant of ligand binding to FPRs. Because bacterial and 
mitochondrial proteins [11, 14] are the only sources of N-formyl 
peptides in nature, it has been widely thought that these receptors 
evolved to mediate trafficking of phagocytes to sites of bacterial 
invasion or tissue damage. Nevertheless, in the last years a large 
number of non-formylated peptide ligands for FPR1 and FPR2 have 
been identified [15].  
 
1.3. Agonists and antagonists 
Since FPRs initial characterisation, and the discovery of 
several members in this receptor family, it has become evident that a 
variety of biological functions could potentially be driven by the large 
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number of molecules able to agonise or antagonise these GPCRs. The 
FPR1 is a high-affinity pattern recognition receptor with the ability to 
track bacteria that release formylated peptides [17]. The receptor also 
binds formylated peptides of mitochondrial origin [16]. Recent work 
reveals that FPR1 also recognizes nonformylated peptides, as well as 
peptides with several other modifications which all bind with high 
affinity and activate the receptor. In addition, FPR1 recognizes and is 
activated by peptides that lack all sequence similarities with the 
peptides originally isolated from bacteria [18]. FPR1 binds N-fMLP 
with high efficiency, whereas FPR2 is defined as a low-affinity N-
fMLP receptor, based on its activation only by micromolecolar 
concentrations of formyl-peptide. FPR2 is the only receptor whose 
ligands include both a formyl-peptide and a lipid, as demonstrated by 
the observation that it also binds. Lipoxin A4 (LXA4) [19]. FPR3 
does not respond to formyl-peptides. FPR2 also shows the ability to 
bind microbe-derived peptides, such as those derived from 
Helicobacter pylori and HIV-1, but it can also respond to 
mitochondrial peptides and synthetic peptides [20].LL37 is a 37 
amino-acid peptide naturally cleaved from the C-terminus of the anti-
microbial protein cathelicidin, which is present in human neutrophil 
granules and epithelial cell surfaces. LL-37 is microbicidal, 
neutralizes endotoxin by direct binding and, in addition, has 
chemotactic activity for human neutrophils, monocytes, and resting T 
cells interacting with FPR2 [20]. Therefore, LL37 could act to amplify 
the innate immune response. FPRs have also been implicated in host 
responses during HIV-1 infection because several synthetic peptides, 
corresponding to amino-acid sequences of HIV-1 envelope proteins 
gp41 and gp120, are chemotactic agonists for FPR2. Annexin I 
(lipocortin I), lipoxin A4 (LXA4) and urokinase-type plasminogen 
activator receptor (uPAR) comprise a second group of newly 
identified host-derived agonists for FPR1 and FPR2, which have 
suggested novel roles for these receptors in the regulation of acute and 
chronic inflammation. From the pathogenic point of view, 
amyloidogenic molecules have been studied as interesting ligands for 
FPR2. This group comprises the acute phase protein serum amyloid A 
(SAA), β-amyloid peptide 42 (Aβ42) [21] and the prion protein-
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derived peptide PrP106-126. The observation that Aβ42 is 
chemotactic and activating for monocytes and microglia cells through 
FPR2, suggests that this receptor is at least partly responsible for 
proinflammatory destructive activity in brain tissue during 
Alzheimer’s disease. The PrP106-126 prion-peptide fragment 
activates FPR2 to induce human monocyte migration and to increase 
the production of the proinflammatory cytokines tumor necrosis factor 
(TNF)-α and IL-1β, both of which are implicated as neurotoxic 
mediators [22]. This suggests that  FPR2 might  participate in 
inflammatory pathology seen in prion diseases. A number of synthetic 
peptides are agonists for FPR2. The first synthetic peptides proposed 
as a specific FPR2 agonist is the WKYMVm (Trp-Lys-Tyr-Met- Val-
D-Met) peptide. It was isolated by screening a synthetic peptide 
library composed of random sequences of hexapeptides and contains a 
D-methionine at position 6 that greatly enhances its biological activity 
[20]. WKYMVm binds to FPR2 with high efficiency and with lesser 
efficiency to FPR1 and FPR3 [23], thereby activating neutrophil and 
monocyte functions, including chemotaxis, mobilization of 
complement receptor-3, cytokine release and activation of NADPH 
oxidase, which results in the respiratory burst. WKYMVm activates 
neutrophils through FPR1 only when signaling through FPR2 is 
blocked, which is indicative of a receptor switch.FPR1 and the closely 
related FPR2 have been linked, in different animal models, to chronic 
inflammation and auto-immune diseases. Through this type of 
research few inhibitors/antagonists have been identified and 
characterized [24].FPR1 is activated by formylated peptides, and 
already 25 years ago it was shown that replacement of the formyl 
group by a tert-butyloxycarbonyl (Boc) group generates a receptor-
specific antagonist wich inhibit chemotactic peptide-induced cell 
activation [25]. An other antagonists of Boc group selective for FPR2 
is the peptide FLFLF (also called Boc-2) containing a tert-
butyloxylcarbonyl (Boc) group at the N-terminus. This peptide 
antagonize the FPR2-agonist serum amyloid A (SAA). Endogenous 
bile acids such as deoxycholic acid (DCA, 1) and chenodeoxycholic 
acid (CDCA, 2) are reported to antagonize FPRs at pathophysiological 
concentrations . These peptides block the access of agonists to the 
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receptor and may interfere with conformational movements of 
extracellular loops linked to receptor activation. Among the novel 
peptides, Trp-Arg-Trp-Trp-Trp-Trp-CONH2 (WRW4) shows the 
most potent activity in terms of inhibiting WKYMVm binding to 
FPR2. WRW4 prevents the activation of FPR2 by WKYMVm, 
resulting in the complete inhibition of the intracellular calcium 
increase, extracellular signal-regulated kinase activation, and 
chemotactic migration of cells toward WKYMVm. WRW4 
specifically inhibits the increase in intracellular calcium by the FPR2 
agonists MMK-1, amyloid β42 (Aβ42) peptide but not by the FPR1 
agonist, fMLP [26]. 
 
1.4. GPCR-mediated cell-surface receptors transactivation 
Cross-communication between different signaling systems 
plays a key role to coordinate the plethora of extracellular stimuli to 
which a cell is subjected under several physiological or pathological 
conditions. Cell-surface receptors are the key components of these 
networks and the inter-receptor crosstalk acts as a general signaling 
mechanism connecting and diversifying signal transduction pathways. 
The major classes of cell surface transmembrane proteins are tyrosine 
kinase receptors (RTKs) and G-protein-coupled receptors (GPCRs), 
which are the largest group of cell-surface seven-transmembrane 
proteins [27]. RTKs activation is achieved by ligand binding to the 
extracellular domain, which can induce dimerization of the receptor 
and, in turn, the autophosphorylation on tyrosine residues within the 
cytosolic domain with the formation of Src homology 2 (SH2) or 
phospho-tyrosine binding (PTB) sites [28]. These represent docking 
sites for the recruitment of SH2-domain-containing proteins or 
adaptor proteins, which trigger intracellular signaling cascades. RTKs 
and GPCRs act in concert to regulate physiological processes and in 
some cases their effects are synergic whereas in others they 
antagonize [29]. The activation of GPCRs can stimulate the signaling 
activity of RTKs connecting the broad diversity of GPCRs with the 
potent signaling capacities of RTKs. Transactivation of RTKs by 
GPCRs signaling can occur through different mechanisms: in a 
ligand-dependent or in a ligand-indipendent manner. In the ligand-
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dependent triple-membrane-passing-signal (TMPS) mechanism, 
GPCR-mediated RTK transactivation depends on activation of 
membrane-bound matrix metalloproteases (MMPs), such as the A 
Disintegrin And Metalloprotease (ADAM) family members wich 
triggers MMP mediated shedding of ligands able to activate RTKs. 
The ligand-independent mechanism instead suggests that GPCR 
stimulation triggers the activation of several second messengers such 
as Ca2+ ions, protein kinase C (PKC), the non-receptor protein 
tyrosine kinases Src and Pyk, β-arrestin and reactive oxygen species 
(ROS) which, in turn, induce tyrosine phosphorylation and subsequent 
activation of RTKs [30]. Several molecular mechanisms allow GPCRs 
to activate Src family kinases, and conversely Src activity plays a 
central role in controlling GPCR responses. Src family tyrosine 
kinases are an integral component of the signal transduction apparatus 
employed by RTKs, playing a key role in cellular growth and 
malignant transformation.In many cases Src family kinases are 
associated with GPCRs through direct interaction with cytoplasmic 
receptor domains, which contain consensus SH3 domain-binding 
motifs or proline-rich motifs within their third intracellular loops or C-
terminal tails, or by binding to GPCR-associated proteins, such as 
heterotrimeric G-protein subunits or β-arrestins. Src family kinases are 
also activated by GPCRs [31]. Transactivation can require the 
generation of oxygen species. ROS can activate many protein tyrosine 
kinases through different mechanisms. In fact, ROS (1) may directly 
activate kinases by altering protein–protein interactions; (2) may 
directly inactivate by oxidation the cysteine residue in the catalytic 
site of protein tyrosine phosphatases, which in turn results in tyrosine 
kinases activation; (3) may stimulate proteolysis of regulatory proteins 
inhibiting tyrosine kinase activity. ROS are produced by a variety of 
extracellular stimuli such as growth factors, GPCR agonists, 
cytokines, ultraviolet radiation, increased osmolarity, and other 
cellular stresses [32]. Sources of their production include 
mitochondria, xanthine oxidase and NADPH oxidase (Nox) family, 
which generate superoxide anion (O2
-), hydrogen peroxide (H2O2), 
and hydroxyl radical (OH·) involved in intracellular redox signaling. 
The pathophysiological effects of these molecules depend on their 
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concentration, subcellular localization and the endogenous antioxidant 
status. Plasma membrane-associated Nox family members are the only 
enzymes that generate ROS as their primary purpose in a highly 
regulated and spatial restricted manner, apparently suited for cell 
signaling and are considered the main source of ROS acutely 
produced upon growth factor or cytokine stimulation [33]. In several 
cell types seven isoforms of the catalytic subunit (Nox1–5, Duox1 and 
2) of NADPH oxidase have been identified.  The NADPH oxidases 
are multimeric protein complexes consisting of up to three cytosolic 
subunits (p47phox, p67phox and p40phox), a regulatory G-protein 
(Rac1 or Rac2) and a membrane-bound cytochrome b558 reductase 
domain [34]. The cytochrome b558 domain includestwo proteins: a 
small α-subunit, p22phox, and a larger, catalytic β-subunit that 
contains binding sites for NADPH and molecular oxygen, as well as 
flavin and heme groups to allow electron transport between the two 
substrates [34]. When cells are exposed to any of a very wide variety 
of stimuli, the cytosolic component p47phox becomes heavily 
phosphorylated and the entire cytosolic complex migrates to the 
membrane, where it associates with cytochrome b558 to assemble the 
active oxidase.The assembled oxidase is now able to transfer electrons 
from the substrate to oxygen [34]. Stimulation of GPCRs with an 
agonist induces p47phox phosphorylation and Nox activation, which 
generates reactive oxygen species (ROS) by O2 using NADPH as 
electron donor. ROS inactivate phosphotyrosine-phosphatases (PTPs) 
by oxidation of a cysteine in the catalytic domain, unbalancing 
intracellular phosphorylation equilibrium. The enhanced activity of 
phosphotyrosine-kinases (PTKs) mediates the trans-phosphorylation 
of tyrosines in the cytosolic region of RTK which, in turn, provide 
docking sites for assembly and activation of signaling complexes 
[35,36].  
 
1.5. Nuclear GPCR 
GPCRs comprise a large family of transmembrane proteins 
activated by a broad range of ligands and implicated in many patho-
physiological processes [37]. Until now, each GPCR and associated 
sets of heterotrimeric G proteins on the cell surface had been proven 
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to initiate one or more chains of intracellular signaling events 
mediated by complexes of GTPases, kinases, and linking proteins. 
Occupancy of a GPCR by its complementary ligand stimulates down-
regulation of expression of the GPCR, by processes that include a 
brief intracellular cycle through endosomes and perinuclear 
vesiculotubular structures, and thereby lead to proteolysis or 
reinsertion in the plasma membrane [38]. New studies of intracellular 
trafficking of a few different GPCRs, evoked by exposure to ligand or 
by cellular activation through ligand-independent mechanisms, have 
shown that GPCRs may be inserted into nuclear membranes for 
prolonged periods, compose distinctive signaling units there, and 
respond to specific intracellular ligand by transducing nuclear 
transcriptional signals that differ from those sent by their plasma 
membrane complexes [39]. Several mechanisms according to which 
GPCRs can significantly influence nuclear events, have been 
proposed. The first consists of the activation of the GPCR complex, 
triggering second messengers which enter in the nucleus and induce 
processes of cellular modification, without leave the membrane. The 
second consists in the entrance in the nucleus of protein fragments of 
GPCRs, that are able to induce ligand-independent signals, or intact 
GPCRs that active trascription factors that directly induce or regulate 
transcriptional events. In other conditions it seems that GPCRs are 
constitutively expressed on the nucleus. Several hypotheses have been 
proposed to elucidate the mechanism(s) by which membrane-bound 
receptors are localized in nuclei, including nuclear import of cleaved 
receptor fragments and chaperone proteins facilitating the removal of 
the receptor from a membrane-embedded state. Presently, the most 
plausible explanation for GPCRs in the nucleoplasm is through 
transport within micelles, which would retain a membrane-embedded 
GPCR suitable for further signaling in cells nuclei [40]. The most 
studied is the molecular mechanism through which intact GPCRs 
localize in nuclear membranes of activated cells, assemble signaling 
complexes there, bind their respective cognate mediators in the 
nuclear domain, and transduce transcriptional signals different from 
those sent to the nucleus by the same GPCRs in the plasma 
membrane. For istance, T cell proliferation by S1P has been linked to 
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signals from type 1 GPCR for S1P (S1P1) in the plasma membrane, 
whereas nuclear S1P1 transduces intracellular S1P suppression of 
proliferation [41]. 
 
1.6. Implications of nuclear signaling by GPCRs 
The nuclear GPCR complexes signal transcriptional events 
different than the corresponding plasma membrane GPCRs. The 
potential biological importance of these GPCRs may be considered on 
three different levels. First, these GPCRs operate differently in pre- 
and post cell activation stages, both in terms of their mechanisms of 
signal transduction and the functional consequences.  Secondly, prior 
to cell activation by a GPCR ligand or other mechanism, plasma 
membrane GPCRs send one type of nuclear signal whereas after cell 
activation and GPCR nuclearization the subsequent nuclear signals 
may have different or even opposite cellular effects [42]. Multiple 
GPCRs have been localized on the nuclear membrane of cardio-
myocytes including angiotensin II type 1 receptor (AT1R) [43], 
angiotensin II type 2 receptor AT2R , α 1AR, β1-AR, β3-AR, and 
endothelin B receptor ETBR. Most of the downstream molecules 
normally associated with GPCR signalling at the plasma membrane 
have also been found in the nucleus. These include all three major 
forms of the G protein α subunit as well as βγ complexes [44]. 
Furthermore, a number of effector molecules have also been shown to 
be located at nuclear level, including cAMP , PLA2, PLCβ1 and 
PLCδ1  as well as a variety of ion channels, including Ca2+, K+and Cl- 
channels [45]. Moreover, the second messengers associated with 
downstream signalling events, including cAMP , IP3 and DAG, are 
also present at the level of the nucleus or generated in isolated nuclei 
[46]. In addition to effectors, many of the systems involved in 
regulation of GPCR signalling are also be found in the nucleus, 
including RGS proteins, β-arrestin-1 and GRKs. This indicates that 
nuclear GPCR signalling is tightly regulated, in a manner analogous to 
their cell surface counterparts, and hence reinforces the idea that these 
receptors are functionally relevant. Furthermore, certain GPCRs, such 
as GABA B receptors, have been shown to interact directly with 
transcription factors [47], while nuclear bradykinin B2 and type I 
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gonadotropin releasing hormone receptors appear to be able to 
regulate histone acetylation, adding yet another potential method by 
which nuclear localized GPCR signalling might modulate gene 
transcription [48]. Nuclear GPCRs can be constitutively activated or 
activated by specific ligands, which are synthesized within the target 
cell or are internalized from the extracellular space (intacrine ligands). 
The potential actions of intracellular ligands include: a) binding to 
intracellular membrane receptors and generation of second 
messengers; b) binding to nuclei and nucleolus; c) binding to 
chromatin; d) binding to receptors on the endoplasmic reticulum (ER) 
immediately following their synthesis, and e) binding to intravesicular 
receptors with consequent generation of second messengers [42]. 
Intracrine ligands can be synthesized and targeted to the Golgi 
apparatus for secretion; however, they may also act intracellularly 
either before or after secretion. Many of these ligands regulate the 
generation of second messengers, translocate and bind to the nucleus, 
and can be pro-angiogenic or anti-angiogenic [49]. Although still 
poorly understood, the diverse functions exerted by agonists and 
hormones acting at intracellular GPCRs suggests that intracrine 
signalling may play important roles distinct from those of the same 
receptors activated at the cell surface. Further confirm the nuclear 
localization of GPCR constitutively expressed, but also internalized in 
a ligand depend or indipendent manner, is supported by the 
recognition of a nuclear localization sequence (NLS). Searches in data 
bank revealed 17 GPCRs with a clearly recognizable NLS motif in the 
eighth helix including adenosine, angiotensin, bradykinin, and 
endothelin receptors. However, a putative NLS motif is located at the 
carboxyl-terminal region of the third intracellular loop in other 
receptors such as apelin receptor [50].  
 
1.7. Scientific hypothesis and aim of the work 
 The G-protein-coupled receptor (GPCR) comprise a large 
family of transmembrane proteins actived by a broad range of ligands 
and implicated in many phato-physiological process [27]. Despite 
GPCRs lack intrinsec tyrosine kinase activity, tyrosine phosporylation 
of RTKs occurs in response to binding of specific agonists of several 
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such receptors, triggering intracellular mitogenic cascades. This 
suggests that the notion that GPCRs are associated with the regulation 
of post-mitotic cell fuctions is no longer believable.GPCRs are able to 
transactive tyrosine kinase receptors (RTKs) and this inter-receptor 
crosstalk acts as a general signaling mechanism connecting and 
diversifying signal transduction pathways. We investigated: 
 The cross-talk between FPR2 and c-Met in primary prostate 
epithelial cells.  
 The cross-talk between FPR1 and VEGFR2 in endothelial 
cells.  
 The role of NADPH oxidase-dependent superoxidase 
generation in RTKs transactivation. 
Current model of GPCRs signalling describe binding of external 
agonists to cell surface receptors which, in turn, trigger several 
biological responses. New paradigms indicate that GPCRs localize to 
and signal at the nucleus, thus regulating distint signalingcascades. A 
full complement of downstream signal trasduction components is 
present on the nuclear membrane including G proteins and enzyme 
effectors. Therefore, the resulting biological effects might result from 
the intregation of extracellular and intracellular signalin pathways. We 
investigated: 
 FPR2 expression on the nuclear membrane in human 
lung cancer (Calu6) and gastric adenocarcinoma (AGS) 
cells.  
 The presence of a nuclear localization sequence (NLS) 
in   FPR2 cDNA sequence. 
 The ability of nuclear FPR2 to trigger specific nuclear 
signaling upon stimulation with its specific synthetic 
ligand WKYMVm. 
Materials and Methods 
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2. Materials and Methods  
2.1. Cell culture 
CaLu-6 cells were obtained from ATCC (Rockville, MD, 
USA) were grown in Dulbecco's modified Eagle's medium (DMEM) 
containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 
μg/ml streptomycin, 1% l-glutamine, and 1% modified Eagle's 
medium. PNT1A,primary prostate epithelial and ECV304 cells were 
purchased from were obtained from ATCC (Rockville, MD, USA) 
and were grown in RPMI supplemented with 10% heat-inactivated 
fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml 
streptomycin and 1% L-glutamine. AGS cells are derived from poorly 
differentiated human gastric adenocarcinoma and were grown as 
monolayer in DMEM (Invitrogen, Grand Island, NY, USA) 
supplemented with 10% fetal calf serum, 100 U/ml penicillin G 
sodium and 100 μg/ml streptomycin sulfate at 37 °C in a humidified 
atmosphere of 5% CO2.Stable FPR2 shRNA-expressing cell lines 
were genereted as described [51]. In short interfering RNA 
experiments 4x 105 cells were incubated for 12 h with 5 nM siRNAs 
in RPMI containing 10% FBS in the presence of 20 ll HiPerFect 
(Qiagen, Hiden, Germany). Cells were then serum-deprived for 24 h 
and stimulated with WKYMVm or N-fMLP. PNT1A cells were also 
stimulated with 10 ng/ml PMA for different times as indicated in the 
figure. HEK293 cells (8x105/well) were seeded in a 6-multiwell and 
transfected with FPR2wt or FPR2mut3 or FPR2mutBis. Briefly, 30 μg 
of plasmids were diluted in 700 μl of DMEM without antibiotics and 
growth factors. 150 μl of this solution was incubated with 10 μl of 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) diluted in 150 
μl of DMEM without antibiotics and growth factors, for 5 min at room 
temperature (RT). DNA complexes were incubated with HEK293 
cells for 24 h at 37 °C. 
 
2.2. RNA isolation 
Total RNA was purified with TRIZOL® (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s instructions and  
retrotranscribed according to the manufacturer’sinstructions by using 
cDNA Synthesis Kit (Invitrogen) in a final volume of 20 μl.  
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2.3. Protein studies 
Protein extractions, immunoblotting and immunoprecipitation 
were carried out according to standard procedures [52]. 
 
2.4. Mutagenesis Assay 
K230A point mutation and H229A/K230A/K231A triple 
mutant within myc-tag-FPR2 fusion protein were generated by using 
Geneart site-directed mutagenesis system kit (Invitrogene, Carlsbad, 
CA, USA) according to the supplier’s instructions. The pCMV6-
ENTRY vector (OriGene Technologies Inc., Rockville, MD, USA) 
containing wild type FPR2 sequence served as the template. The 
forward and reverse primers to create K230A mutant were 5’-
GCAGCCAAGATCCACGCAAAGGGCATGATTAA-3’ and 5’-
TTAATCATGCCCTTTGCGTGGATCTTGGCTGC-3’, respectively. 
The forward and reverse primers to produce the 
H229A/K230A/K231A triple change were 5’-
ATTGCAGCCAAGATCGCCGCAGCGGGGCATGATTAAATC-3’ 
and 5’-
GATTTAATCATGCCCGCTGCGGCGATCTTGGCTGCAAT-3’, 
respectively. Mutant FPR2 clones were selected with kanamycin and 
the resulting plasmids FPR2mut3 and FPR2mutBis were purified by 
maxi-prep (Qiagen, Hiden, Germany). The mutations were confirmed 
by DNA sequencing on an ABI 3130 xl Gene Analyzer Sequencer 
(CEINGE Biotecnologie Avanzate s.c.a.r.l., Naples, Italy). 
 
2.5. Immunofluorescence 
Briefly, CaLu-6 cells, or HEK293 cells transfected with 
FPR2wt or FPR2mut3 or FPR2mutBis were washed in PBS 
containing Ca2+ and Mg2+, fixed in 4% paraformaldehyde (PFA) for 
20 min at RT and quenched with 50 mM NH4Cl for 10 min at RT. 
After blocking with 1% BSA in PBS for 10 min, cells were 
permeabilized in 0.2% TritonX-100 (Sigma, Saint Louis, MO, USA) 
1% BSA in PBS for 10 min at RT. Cells were then washed in 1% 
BSA in PBS at RT and incubated with anti-FPR2 (1:100; 
Thermoscientific, Waltham, MA, USA) or anti-LAP2 (1:100; Santa 
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Cruz Biotechnology, CA, USA) antibodies, for 20 min. Cells were 
washed with 1% BSA in PBS and stained with goat anti-mouse Alexa 
Fluor 488 (1:200; Invitrogen, Carlsbad, CA, USA) or donkey anti-
goat Alexa Fluor 680 (1:200; Invitrogen, Carlsbad, CA, USA) 
secondary antibodies, for 1 h at RT. Staining was performed by 
incubating cells with DAPI (1 μg/ml; Invitrogen, Carlsbad, CA, USA) 
in PBS for 10 min. Cells. were then washed with 1% BSA in PBS and 
images were captured by using a Zeiss LSM 510 meta confocal 
microscope equipped with an oil immersion plan Apochromat 
63×objective 1.4 NA.  
 
2.6.Receptor binding assay 
Radioligand binding assays were performed as described [53]. 
 
2.7. Statistical analysis 
All the presented data are expressed as means ± S.D. and are 
representative of three or more independent experiments. Statistical 
analyses were assessed by Student’s t test for paired data. Results 
were considered significant at p<0.05. 
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3. Results 
3.1. PNT1A cells express a functional FPR2 receptor 
Cross talk between cell surface receptors, such as G-protein-
coupled receptors (GPCRs) and receptortyrosine kinases (RTKs), is a 
crucial signaling mechanism to expand the cellular communication 
network. We analyze the cross-talk between FPR2 and c-Met in 
PNT1A cells to identify intracellular signalling cascades triggered by 
the WKYMVm-mediated activation of HGF receptor.Wefirst 
analyzed the expression of FPR2 in membrane, cytoplasmic and total 
proteins purified by PNT1A cells. We detected the presence of the 
band corresponding to FPR2 protein at the expected molecular size on 
membrane extracts by using an α-FPR2 antibody (Fig. 1A). By RT-
PCR we detected FPR2 but not FPR1 and FPR3, providing the first 
evidence of FPR2 expression in these cells. (Fig.1B). In IMR90 
fibroblasts and in human lung cancer cells, stimulation of FPR2 with 
10 μM WKYMVm induces p47phox phosphorylation, which is 
considered the key event for NADPH oxidase-dependent superoxide 
generation [54]. In immunoblot experiments we observed that in 
PNT1A cells p47phox results phosphorylated on serine residues 
within the first 2 min of stimulation with the FPR2 agonist (Fig.1C) 
and that preincubation with PTX or with the FPR2 antagonist WRW4 
peptide, significantly prevents p47phox serine phosphorylation (Fig. 
1D). Furthermore, stimulation of FPR2 by WKYMVm induces 
NADPH oxidase-dependent superoxide generation with maximal 
production occurring at 2 min (Fig.1E), indicating that FPR2 is a 
biologically functional receptor in PNT1A cells. 
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Fig.1. FPR2 is a functional receptor in PNT1A cells. (A) Membrane (Membr.), cytoplasmic 
(Cyt.) and whole (Tot.) lysates (50 μg) were analyzed by western blot with an α- FPR2 
antibody. (B) cDNAs from PNT1A cells, PMN and monocytes (mon.) were coamplified by 
using FPRs and GAPDH primers; (C) Cell were exposed to WKYMVm for the indicated 
times, or (D) preincubated with PTX or WRW4 before stimulation. Whole lysates (1 mg) 
were immunoprecipitated with an a-p47phox antibody and p47phox serine phosphorylation 
was detected by using an α-p-Ser antibody. An α-p47phox antibody served as a control for 
protein loading. (E) Superoxide production was determined as the SOD-sensitive rate of 
reduction of cytochrome c.P < 0.05 compared with unstimulated cells. 
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3.2. FPR2 activation promotes the phosphorylation of Y1313/Y1349/ 
Y1356 residues of c-Met 
Cross-talk between GPCRs and TKRs plays an instrumental 
role in orchestrating downstream signalling molecules. We analyzed 
the ability of FPR2 to transactivate c-Met and, in 
immunoblotexperiments, we observed that stimulation with 
WKYMVm induces the time-dependent phosphorylation of the HGF 
receptor (Fig. 2A). In particular, the FPR2 agonist promotes the 
phosphorylation of Y1313/Y1349/Y1356 residues of c-Met within the 
first 2 min which decreases after 5 min of stimulation, both in PNT1A 
(Fig. 2B) and primary prostate epithelial cells (Fig. 2C). Furthermore, 
preincubation of PNT1A cells with the c-Met inhibitor SU11274 or 
PTX or WRW4 (Fig. 2D), or with siRNAs against FPR2 or c-Met 
(Fig. 2E), before WKYMVm stimulation, results in a significant 
reduction in the phosphorylation level of these tyrosines. Oxidation 
and/or reduction of cysteine sulfhydryl groups of phosphotyrosine 
phosphatases (PTPases) tightly controls the activity of TKRs. Nox 
family is considered the main cytosolic source of ROS which can 
contribute to TKR transactivation by inhibiting a PTPase activity [50] 
and, in turn, shifting the equilibrium state of TKR from non-
phosphorylated to phosphorylated. We preincubated cells with the 
NADPH-oxidase-specific inhibitor apocynin or with a siRNA against 
p22phox before WKYMVm stimulation, and we observed that 
blockade of NADPH oxidase function prevents FPR2-induced 
phosphorylation of Y1313/Y1349/Y1356 residues of c-Met (Fig. 2F). 
We also incubated cells with PMA, an oxidase inducer, and we 
observed that it promotes the phosphorylation of Y1349 and Y1356 
residues, but not of Y1313 residue, only after 5 min and with a kinetic 
different from that induced by FPR2 stimulation(Fig. G). This 
suggests that FPR2-mediated ROS production plays a crucial role in 
the FPR2/HGF cross-talk mechanism. 
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Fig.2. FPR2 activation results in c-Met trans-phosphorylation. (A) Whole lysates (800 μg) from 
PNT1A cells were immunoprecipitated with an α-cMet antibody and c-Met tyrosine phosphorylation 
level was detected with an α-pY antibody. PNT1A (B) or primary prostate epithelial cells (C) were 
stimulated with WKYMVm for the indicated times. (D) PNT1A cells were preincubated with PTX or 
WRW4 or SU11274, or (E) with siRNAs against FPR2 (FPR2 siRNA) or siRNA against c-Met (c-Met 
siRNA), or (F) withsiRNA against p22phox (p22phox siRNA) or with apocynin, before stimulation. A 
negative control siRNA (NC siRNA) was included in the experiments. (G) PNT1A cells were stimulated 
with PMA for the indicated times. Whole lysates (50 μg) were subjected to immunoblotting analysis and 
phosphorylation of Y1313/Y1349/Y1356 residues of c-Met was detected with α-p-cMet(1313), α-p-
cMet(1349) or α-p-cMet(1356) antibodies. P < 0.05 compared with unstimulated cells. 
 
3.3. FPR2/c-Met cross-talk triggers STAT3 pathway 
The single multifunctional docking site located in the C-
terminus of the HGF receptor contains the sequence 
Y1349VHVNATY1356- VNV, which provides binding sites for a 
variety of SH2-containingsignal transducers and effectors. STAT3 
binds to the sequence following the phosphorylated Y1356 residue 
[54]and its association with c-Met results in the phosphorylation of a 
conserved tyrosine residue (Y705), which is required for promoting 
the dimerization of STAT3. Activated STAT3 is then translocated in 
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the nucleus where it acts as a transcriptional factor. Full 
transcriptional activityand DNA binding capacity are manifested only 
when the serine 727 residue of STAT3 is also phopshorylated. In 
time-dependent western blot experiments, we observed that 
WKYMVm induces the rapid phosphorylation of Y705 and S727 
residues of STAT3 (Fig. 3A), as well as the nuclear translocation of 
activated STAT3 (Fig. 3B). We also preincubated cells with PTX or 
WRW4 or SU11274 (Fig. 3C), or with siRNAs against FPR2 or c-Met 
(Fig. 3D), and we observed that these treatments prevent the 
WKYMVm-induced activation of STAT3. Furthermore, we 
blockaded NADPH oxidase function by pretreating cells with 
apocynin or with a siRNA against p22phox and we observed that 
FPR2-induced phosphorylation of Y705 and S727 residues of STAT3 
was prevented (Fig. 3E). 
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Fig.3. FPR2 activation triggers STAT3 pathway. (A) PNT1A cells were stimulated for the indicated 
times with WKYMVm and specific phosphorylation of STAT3 was detected with α-pSTAT3(Y705) or α-
pSTAT3(S727) antibodies. An α-STAT3 antibody served as a control for protein loading. (B) STAT3 
nuclear translocation was analyzed on nuclear extracts (50 μg) with an α-STAT3 antibody. The same 
filter was reprobed with an a-cyclin A antibody. (C) Cells were preincubated with PTX or SU11274 or 
WRW4, or (D) with FPR2 siRNA or c-Met siRNA, or (E) with a p22phox siRNA or apocynin, before 
WKYMVm stimulation. A NC siRNA was included in the experiments. Proteins (50 μg) were subjected 
to immunoblotting analysis with α-p-STAT3(Y705) or α-p-STAT3(S727) antibodies.P < 0.05 compared 
with unstimulated cells. 
 
3.4. FPR2-induced c-Met trans-phosphorylation generates specific 
docking sites for PLC-cγ 
Signal transducers that bind sequences surrounding tyrosines 
1349 and 1356 residues in c-Met can interact with the receptor either 
directly or indirectly through the scaffolding protein Gab1, which 
represents the key coordinator of the cellular responses toc-Met [55]. 
After the interaction with the receptor, Gab1 becomes phosphorylated 
on several tyrosine residues that, in turn, recruit a number of 
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signalling effectors, including PLC-γ1 which can weakly bind c-Met 
also directly [55]. We analyzed PLC-γ1 activation in WKYMVm-
stimulated PNT1A cells and we observed in time-course experiments 
that the FPR2 agonist induces PLC-γ1 activation with maximal 
phosphorylation of Y783 residue occuring at 2 min (Fig.4A). PLC-
γ1(Y783) phosphorylation is prevented by preincubation with PTX or 
WRW4 or SU11274, before WKYMVm stimulation (Fig.4B). We 
also analyzed the PKC isoforms activated as a consequence of the 
hydrolysis of phosphatidylinositol-4-5-bisphosphate by PLC-γ1, by 
analyzing the cellular partitioning of PKC isozymes in growth-
arrested and WKYMVm-stimulated cells. In response to the FPR2 
agonist, of the seven PKC isoenzymes that we examined (data not 
shown) only PKCα translocates to the membrane fraction and a 
significant increase in the amount wasdetected within 2 min of 
exposure to WKYMVm (Fig.4C). In contrast, no translocation of 
PKCδ and PKCε was observed (Fig.4C). Furthermore, the Gi protein 
specific inhibition, or a specific FPR2 antagonist, or an inhibitor of c-
Met kinase activity, completely prevents PKCα activation (Fig.4D), 
suggesting that it depends on FPR2-dependent c-Met phosphorylation. 
 
 
 
Fig.4. FPR2-induced c-Met transactivation generates specific docking sites for PLC-γ. (A) Proteins 
were purified from PNT1A cells exposed to WKYMVm for the indicated times, or (B) preincubated with 
PTX or SU11274 or WRW4, before Nstimulation. Fifty micrograms of lysates were analyzed with an α-
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pPLC-γ(Y783) antibody. (C) Translocation of PKC isoforms was analyzed on membrane extracts (30 μg) 
with α-PKCα or α-PKCδ or -PKCε antibodies. (D) Cells were preincubated with PTX, or SU11274 or 
WRW4 before stimulation and 30 μg of purified membrane proteins were analyzed with an-PKC 
antibody. The same filter was reprobed with an a-cMet antibody. 
 
3.5. FPR2-induced activation of the multifunctional docking site of 
c- Met triggers PI3K/Akt pathway 
Nine domains of Gab1 containing a single tyrosine are 
phosphorylated in vitro by HGF and three of these tyrosines (Y458/ 
Y473/Y590) bind the p85 regulatory subunit of PI3K. In HGF 
receptor there is also an other recognition motif (Y1313EVM) which 
can represent a potential binding site for PI3K. In immunoblotting 
experiments we observed that WKYMVm induces PI3K(p85) 
phosphorylation within 2 min of stimulation (Fig.5A). This is 
prevented by pretreating cells with PTX, or SU11274, or WRW4, or 
apocynin (Fig.5B). PI3K is the key component for the activation of 
Akt signalling. In the PI3K/Akt pathway, formation of 3-
phosphoinositides by PI3K enables the activation of Akt by 
phosphoinositide-dependent protein kinases 1 and 2, which 
phosphorylate Akt at threonine 308 and serine 473 residues, 
respectively. We analyzed PI3K(p85) activity by analyzing Akt 
phosphorylation in response to FPR2 stimulation and the results 
showed that WKYMVm induces Akt(S473) phosphorylation within 
the same time frame as PI3K(p85) phosphorylation (Fig.5C). The 
preincubation of cells with highly selective PI3K inhibitors or PTX or 
WRW4 or SU11274 (Fig.5D), or with siRNAs against FPR2 or c-Met 
(Fig.5E), or with a siRNA against p22phox (Fig.5F), significantly 
prevents WKYMVm-induced Akt (S473) phosphorylation. 
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Fig.5. FPR2/c-Met cross-talk triggers the activation of PI3K/Akt pathway. (A and C) Cells were 
exposed with WKYMVm for the indicated times or (B) preincubated with PTX or SU11274 or WRW4 or 
apocynin, or (D) with PTX or WRW4 or Wortmannin or LY294002 or SU11274, or (E) with FPR2 
siRNA or c-Met siRNA, or (F) with a p22phox siRNA, before stimulation. A NC siRNA was included in 
the experiments. Proteins (50 μg) were analyzed with (A and B) an -pPI3K(p85) antibody, or (C, D, E 
and F) with an -pAkt( S473) antibody. An-Tubulin antibody was used as a control of protein loading. 
P < 0.05 compared with unstimulated cells. 
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3.6.FPR1 is a biologically functional receptor in ECV cells 
The Vascular endothelial growth factor (VEGFR2) is a cell 
surface receptor for vascular endothelial growth factor.We analyzed 
the expression of FPRs and NOX enzymes in ECV cells. By RT-PCR 
we detected FPR1 but not FPR2 and FPR3, and NOX2 and NOX4 
isoforms of NADPH oxidase, providing the evidence of FPR1 and 
NADPH expression in endothelial cells (Fig.6). 
 
 
Fig.6. ECV cells express FPR1 on the plasma membrane. cDNA from ECV, limphatic and HUVEC  
cells were coamplified by using FPRs, NOXs and GAPDH primers.  
 
We first analyzed the ability of FPR1 to activate NOXs. 
Phosphorylation and membrane translocation of the cytosolic oxidase 
subunits are considered key events in the assembly of phagocytic and 
nonphagocytic NADPH oxidase.Western blot analysis showed that  
NADPH oxidase regulatory subunit p47phox is rapidly 
phosphorylated on serine residues upon exposure to N-fMLP (Fig.7A) 
and that this is prevented by preincubation with PTX (Fig.7B). 
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Fig.7. FPR1is a fuctional receptor in ECV cells. (A) Cell were exposed to N-fMLP for the indicated 
times, or (B) preincubated with PTX before stimulation. Whole lysate (1mg) were immunoprecipitated 
with an -p47phox antobody and p47phox serine phosphorilation was detected by using an -p-Ser 
antibody. An -p47phox antibody served as a control for protein loading.P < 0.05 compared with 
unstimulated cells. 
 
3.7. NADPH-oxidase-dependent superoxide generation is required 
for FPR1-induced VEGFR2 transactivation 
Cross-communication between different signaling systems 
plays a key role to coordinate the plethora of extracellular stimuli to 
which a cell is subjected under several physiological or pathological 
conditions. Cell-surface receptors are the key components of these 
networks and the inter-receptor crosstalk acts as a general signaling 
mechanism connecting and diversifying signal transduction pathways. 
We analyzed the ability of FPR1 to transactivate VEGFR2.   We 
observed that stimulation with the FPR1 agonist promotes the 
phosphorylation of Y996 residues of VEGFR2 in in time-dependent 
manner (Fig.8A). Furthermore, preincubation of ECV cells with PTX, 
before N-fMLP stimulation, results in a significant reduction in the 
phosphorylation level of this tyrosine (Fig.8B). NADPH oxidase is 
considered the main cytosolic source of ROS, which are able to 
inactivate phosphotyrosine-phosphatases (PTPs) by oxidation of a 
cysteine in the catalytic domain, unbalancing intracellular 
phosphorylation equilibrium. The enhanced activity of 
phosphotyrosine-kinases (PTKs) can mediate the trans-
phosphorylation of tyrosines in the cytosolic region of RTKs. We 
preincubated cells with the NADPH-oxidase-specific inhibitor 
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apocynin or with a siRNA against p22phox before N-fMLP 
stimulation, and we observed that blockade of NADPH oxidase 
function prevents FPR1-induced phosphorylation of Y996 residues of 
VEGFR2 (Fig.8C ). 
 
Fig.8. FPR1 activation results in VEGFR2 trans-phosphorilation. (A) ECV cells were stimulated for 
indicated times with N-fMLP and VEGFR2 tyrosine phosphorilation level was detected with an -p-
VEGFR2(Y996) antobody. (B) ECV were preincupated with PTX, or (C) with a siRNA against p22phox 
(p22phox siRNA) or with apocynin, before stimulation. A negative control siRNA (NC siRNA) was 
included in the expreriments. Proteins (50 μg) were subjected to immunoblotting analysis with an  p-
VEGFR2(Y996) antibody. -GAPDH antibody was used as a control of protein loading. P < 0.05 
compared with unstimulated cells. 
 
These results suggests that ROS production plays a crucial role in 
FPR1/VEGFR2 cross-talk mechanism. 
 
3.8. FPR1/VEGFR2 cross-talk triggers STAT3 pathway 
The trans-phosphorylation of tyrosines in the cytosolic region 
of VEGFR2 provide docking sites for assembly and activation of 
signaling complexes. Since VEGFR mediates angiogenesis via 
STAT3 pathway,we analized STAT3 activation by phosphorylation of 
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its conserved tyrosine residue (Y705) which is required for promoting 
the STAT3 dimerization. Activated STAT3 is then translocated in the 
nucleus where it acts as a transcriptional factor. Full transcriptional 
activity and DNA binding capacity are manifested only when the 
serine 727 residue of STAT3 is also phosphorylated. We observed that 
N-fMLP induces the phosphorylation of Y705  and Ser727 of STAT3 
in time-dependent manner  (Fig.9A). We also preincubated cells with 
PTX (Fig.9B) and we observed that this treatment prevents the N-
fMLP induced activation of STAT3. Furthermore, we blockaded 
NADPH oxidase function by pretreating cells with apocynin or with a 
siRNA against p22phox and we observed that FPR1-induced 
phosphorylation of Y705 residue of STAT3 was prevented 
(Fig.9C,D). We observed also the nuclear translocation of activated 
STAT3 (Fig.9E ). 
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Fig.9. FPR1 activation triggers STAT3 pathway. (A) ECV cells were stimulated for the indicated times 
with N-fMLP and specific phosphorylation of STAT3 was detected with -pSTAT3(Y705) or -
pSTAT3(S727) antibodies (B) Cells were preincubated with PTX  (C,D) or apocynin or with a p22phox 
siRNA, before N-fMLP stimulation (C,D). A NC siRNA was included in the experiments. Proteins (50 
μg) were subjected to immunoblotting analysis with -p-STAT3(Y705) or -p-STAT3(S727) antibodies. 
STAT3 nuclear translocation was analyzed on nuclear extracts (50 μg) with an a-STAT3 antibodyThe 
same filter was reprobed with an -YY1 antibody. P < 0.05 and P < 0.05 compared with unstimulated 
cells. 
 
3.9. FPR1-induced VEGFR trans-phosphorylation generates 
specific docking sites for PLC-Cγ 
PLC is rapidly tyrosine-phosphorylated and associated with 
VEGFR2 both in endothelial cells and NIH3T3 cells [56]. We 
analyzed PLC-γ activation in N-fMLP stimulated ECV cells and we 
observed in time-course experiments that the FPR1 agonist induces 
PLC-γ activation with maximal phosphorylation occuring at 1 min. 
(Fig.10A). We also analyzed the PKC isoforms activated as a 
consequence of the hydrolysis of phosphatidylinositol-4-5-
bisphosphate by PLC-γ. In response to the FPR1 agonist, PKC α and δ 
translocates to the membrane fraction and a significant increase in the 
amount was detected within 2’ min of exposure to N-fMLP (Fig.10B).  
 
 
Fig.10.VEGFR2 transactivation generates specific docking site for PLCγ. (A) Proteins were purified 
from ECV cells exposed to N-fMLP for the indicated times. 80 μg of lysate were analyzed with an-p-
PLCγ antibody. (B) traslocation of PKC isoforms was analyzed on membrane extracts (30μg) with -
PKC or -PKC δ antibody. The same filter was reprobed with an-VEGFR2 antibody. 
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3.10.FPR1-mediatedPI3K/AKT pathway requires VEGFR2 
activation 
We analyzed PI3K(p85) activity by analyzing Akt 
phosphorylation in response to FPR1 stimulation and the results 
showed that N-fMLP induces Akt(S473) phosphorylation (Fig.11A). 
The preincubation of  ECVcells with PTX(Fig.11B) or apocynin or 
with a siRNA against p22phox (Fig.11C,D), significantly prevents N-
fMLP-induced Akt(S473) phosphorylation. The preincubation with 
highly selective PI3K inhibitors also prevents Akt phosphorylation 
(Fig.11E). 
 
Fig.11. FPR1/VEGFR2 cross-talk triggers the activation of PI3K/Akt pathway. (A) ECV cells were 
exposed with N-fMLP for the indicated times or (B) preincubated with PTX (C) or apocynin, or (D) with 
a p22phox siRNA, or Wortmannin or LY294002  (E) before stimulation.. Proteins (50 μg) were analyzed 
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with an  p-AKT( S473) antibody.-GAPDH  antibody was used as a control of protein loading. P < 0.05 
compared with unstimulated cells. 
 
3.11. FPR2 is expressed in nuclear fraction of Calu-6 and AGS cells 
The expression of several functional GPCRs is not exclusively 
restricted to the plasma membrane but is also extended to different 
compartments, including the nuclear membrane. Many of the observed 
nuclear effects elicited by these receptors are not prevented by 
classical inhibitors, that exclusively target cell surface GPCRs, 
presumably because of their structures, lipophilic properties, or 
affinity for nuclear receptors. Furthermore, these intracellular 
receptors may regulate signaling cascades that differ from those of 
their cellular membrane counterparts [29].We isolated membrane, 
cytosolic and nuclear fractions from CaLu-6 and AGS human cells 
and we examined FPRs subcellular distribution by western blot. The 
results show that an anti-FPR2 antibody, but not anti-FPR1 or anti-
FPR3 antobodies (data not shown), detects the receptor in membrane 
and  nuclearfractions  of Calu6 (Fig.12A) and AGS (shCRT) cells 
(Fig.12B).  In gastric cells (AGS) stably trasfected  with a short 
hairpin (shRNA) that targets FPR2 (shFPR2) nuclear expression is 
prevented compared with AGS cells stably transfected with a shRNA 
control (AGSshCRT) ( Fig.12C).   The purified cellular components 
were validated by using anti-LAP2, anti-CD44 and anti-RAB7 and 
tubulin antibodies, for nuclear  membrane, lysosome and cytosolic  
fractions, respectively. Confocal microscopy in Calu6 cells revealed a 
fluorescent signal for FPR2 (green) distributed intracellularly (Fig. 
12D, Panel A) and, as expected, an intense fluorescent signal for 
LAP2 (Fig. 12D, Panel B) on the nuclear membrane (red). By using 
Imaris image analysis software, we demonstrated that FPR2 
colocalizes  with the nuclear LAP2 (yellow/orange) (Fig.12D, Panel 
C). 
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Fig.12. Nuclear FPR2 expression in CaLu-6 cells. (A-B-C) Membrane (M), cytosolic (C) and nuclear 
(N) fractions were purified from CaLu-6 and AGS cells. Protein extracts (30 μg) were resolved on 10% 
SDS-PAGE and immunoblots were probed with -FPR2. -EGFR, -LAP2, -CD44, -RAB7 or -
Tubulin were used as markers for fractionation purity and as loading control. (D) Confocal 
immunofluorescence microscopy of CaLu-6 cells. Localization of FPR2 was detected by incubating cells 
with an -FPR2 antibody. Cells were then washed in 1% BSA in PBS and incubated with goat anti-
mouse Alexa Fluor 488-conjugated secondary antibody (Panel A; green). Nuclear protein LAP2 was 
detected by incubating cells with -LAP2 antibody for 20 min and with secondary donkey anti-goat 
Alexa Fluor 680 antibody for 1 h (Panel B; red). Staining was performed by incubating cells with DAPI. 
Merged signals (Panel C; yellow/orange) show co-localization of FPR2 and LAP2 (arrows). Cells showed 
no staining with secondary antibody alone. Data are representative of three independent experiments. 
 
Following stimulation with the appropriate agonist, several GPCRs 
have been detected in the perinuclear or nuclear regions, this 
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localization can be attributed to translocation of a GPCR from the cell 
surface or de novo synthesis of the receptor [30]. 
 
3.12. FPR2 amino acid sequence contains a NLS in the third 
intracellular loop 
Nuclear localization of proteins requires a NLS characterized 
by a short stretch of basic amino acid residues. This is recognized by 
members of the importin family, which act as carriers to transport the 
substrate protein across the nuclear pore structure [50]. Nuclear 
GPCRs might be derived from the cell membrane and their transfer to 
the nucleus can be attributed to a nuclear localization motif. We 
analyzed FPR2 sequence for the search of NLS by using cNLS 
mapper program and the results identified a stretch of basic 
aminoacids in the third cytoplasmic loop of the receptor (Fig.13). 
 
 
Fig.13. Schematic representation of the human FPR2. The putative NLS in the third intracellular loop, 
containing basic aminoacids,. 
 
Apelin Receptor and Urotensin II receptor, which are members of the 
GPCR family, also show the presence of a NLS in the third 
cytoplasmic loop. However, a NLS could not be required for nuclear 
localization. In fact, endothelin receptor subtypes A and B, which 
have a perinuclear distribution, localize to the nuclear membrane via 
de novo synthesis and retrograde transport [40].  
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3.13. [I125]WKYMVm specifically binds FPR2 in isolated nuclei 
To determine whether nuclear FPR2 immunoreactivity was 
representive of the presence of a functional ligand-binding receptor, 
radioligand binding assays were performed on nuclei purified from 
CaLu-6 cells. The experiments, performed using [125I]WKYMVm, 
revealed a binding that was specifically displaced by increasing 
concentrations of unlabeled ligand in a concentration-dependent 
manner (Fig14A). The saturability of the binding sites for 
[125I]WKYMVm was tested by adding increasing concentrations of 
the radioligand, and receptor binding analysis performed with the 
Origin program predicted a Kd of 245 pM (Fig.14B ). 
 
 
 
Fig.14 Specific binding of [125I]WKYMVm to nuclear FPR2. (A) Purified nuclei from CaLu-6 cells 
were incubated for 90 min at 30 °C in binding buffer containing 0.5 nM [125I]WKYMVm and increasing 
concentrations of unlabeled peptide, as indicated. (B) Nuclei were incubated with increasing 
concentrations of the radioligand in binding buffer supplemented (non-specific binding) or not (specific 
binding) with a 1000-fold molar excess of unlabeled WKYMVm, as indicated, for 90 min at 30 °C. 
Specific binding was determined by the difference between total and non-specific binding. Radioactivity 
was quantified using a β-counter. The experiments were performed in triplicate. 
 
3.14. Nuclear-associated FPR2 is a functional receptor 
The physiological functions of nuclear GPCRs are poorly 
understood. They can regulate signaling pathways that differ from 
those of their counterparts at the cell surface and the consequent 
biological responses could result from the integration of extracellular 
and intracellular signaling events [29].Therefore, to evaluate whether 
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nuclear-associated FPR2 was active, we co-immunoprecipated FPR2 
and Gαi from purified nuclei stimulated or not stimulated with 
WKYMVm and we determined Gαi expression levels by western blot 
analysis in Calu6 and AGS cells. In untreated cells we observed a 
basal level in Gαi expression, which decreased upon stimulation with 
WKYMVm (Fig. 15A,B) in both cell lines. In AGS(shFPR2) cells 
where FPR2 expression is silenced with a specific shRNA we didn’t 
observe Gαi nuclear expression compared to control (Fig15C).  These 
results suggest that nuclear-associated FPR2 is a functional receptor 
and can respond to a specific agonist. 
 
 
Fig.15.Nuclear FPR2 is a functional receptor. (A-B-C) Nuclei were isolated from CaLu-6 and AGS 
cells stimulated with 10 μM WKYMVm for 5 min. Nuclear lysates (400 μg) were immunoprecipitated 
with α-FPR2 and electrophoresed by SDS-PAGE. Immunocomplexes were probed with α-Gi or α-FPR2 
antibodies.  
 
Effectors associated  with post G protein GPCR signaling, including 
mitogen-activated protein kinase (MAPK) pathway, is also present in 
the nucleus. Therefore, we tested the functionality of nuclear-
associated FPR2 by assessing the ability of the receptor to activate 
ERKs. p42MAPK and p44MAPK are nuclear and cytoplasmic protein 
kinases and in both compartments MAPK signal transduction system 
is regulated by serine/threonine phosphorylation [57]. Isolated intact 
CaLu-6  and AGS (shCRT)  nuclei were stimulated with WKYMVm 
for different times and nuclear lysated were incubated with an α-
pERK antibody. The results showed a time-dependent 
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phosphorylation of nuclear p42MAPK, but not of p44MAPK (Fig.16 
A,B), which was prevented by preincubation with the antagonist 
peptide WRWWWW (Fig. 16 C,D) in both cell lines. 
 
 
Fig.16.Nuclear FPR2 is a functional receptor. (A and B) Nuclei were purified from serum-deprived 
CaLu-6  and AGS(CRT) cells and stimulated with 10μM WKYMVm for the indicated times or (C and D) 
preincubated with the indicated concentration of WRWWWW (WRW4) before stimulation. Nuclear 
lysates (30 μg) were resolved on 10% SDS–PAGE.  ERK phosphorylation was detected by western blot 
with an α-phospho-ERK antibody (α-pERK). The arrow indicates the phosphorylated form of p42MAPK 
(pERK2). An α-ERK antibody served as a control for protein loading. The arrows indicate the non-
phosphorylated forms of ERK1 and ERK2. All the blots are representative of three separate experiments 
of identical design. Protein phosphorylation levels were quantitatively estimated by densitometry using a 
Discover Pharmacia scanner equipped with a Sun Spark Classic densitometric workstation. *p<0.05 and 
°p<0.05 compared with unstimulated nuclei. 
 
Activated MAPK phosphorylate and activate several transcription 
factors, such as c-Jun and c-Myc, resulting in the modulation of genes 
associated with proliferation. Furthermore, the activation of FPR2 
with WKYMVm effectively phosphorylates c-Jun N-terminal kinase 
(JNK) [58]. In order to activate gene expression, transcription factors 
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have to localize to the nucleus. Nuclear abundance of c-Jun correlates 
with target gene activity and excessive c-Jun activation can drive cells 
towards apoptosis or changes in differentiation, whereas decreased c-
Jun function can reduce proliferation. c-Myc is located predominantly 
in the nucleus where it is found in a dispersed granular nucleoplasmic 
pattern and can be directly phosphorylated by ERKs. We analysed c-
Jun and c-Myc activation in purified nuclei of Calu-6 and 
AGS(shCRT) cells stimulated with WKYMVm and we observed a 
time-dependent phosphorylation of the two transcriptional factors 
(Fig.17A,B), which was prevented by the preincubation with the 
FPR2 antagonist (Fig.17C,D).  
 
 
Fig.17.Nuclear FPR2 is a functional receptor. (A and B) Nuclei were purified from serum-deprived 
CaLu-6  and AGS cells and stimulated with 10μM WKYMVm for the indicated times or (C and D) 
preincubated with the indicated concentration of WRWWWW (WRW4) before stimulation. Nuclear 
lysates (30 μg) were resolved on 10% SDS–PAGE. c-Jun and c-Myc phosphorylation was detected with 
α-phospho-Jun (α-p-Jun) and α-phospho-Myc (α-p-Myc) antibodies, respectively. α-Tubulin and α-YY1 
were used as markers for nuclear purity. All the blots are representative of three separate experiments of 
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identical design. Protein phosphorylation levels were quantitatively estimated by densitometry using a 
Discover Pharmacia scanner equipped with a Sun Spark Classic densitometric workstation. *p<0.05 and 
°p<0.05 compared with unstimulated nuclei.  
 
These results indicate that nuclear (or perinuclear) FPR2 might play a 
more direct role in regulating gene expression and our in progress 
studies are aimed to identify which genes are regulated by nuclear 
FPR2. 
 
3.15. NLS mutagenesis analysis. 
To test whether the putative NLS located in the third 
intracellular loop of FPR2 was required for the nuclear localization of 
the receptor, we performed single and multiple mutagenesis in a Myc-
tagFPR2 construct, substituting the basic residue K230 into Alanine 
(FPR2mut3) and  H229, K230 and K231 into non-polar aminoacids 
Alanine, whithin the 227-KIHKK-231 sequence (FPR2mutBis) 
(Fig.18A). FPR2wt and the two mutated constructs were individually 
overexpressed in HEK293 cells and analysed by immunofluorescence. 
The results show that fluorescence was partially localized in the 
nucleus of cells transiently transfected with Myc-tagFPR2wt or Myc-
tagFPR2mut3 (K230A point mutation) (Fig. 18B, Panels B and C). In 
contrast, nuclear localization of FPR2 was abolished in cells 
transfected with Myc-tagFPR2mutBis (H229A/K230A/K231A triple 
mutant) (Fig. 18B, Panel D). 
 
 
 
 
A 
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Fig.18. FPR2 aminoacid sequence contains a NLS. (A) The aminoacid sequence of NLS in the third 
intracellular loop of FPR2 is boxed in red. The mutated aminoacids are shown in white in the indicated 
mutant constructs. (B) HEK293 cells were transfected with FPR2wt or FPR2mut3 or FPR2mutBis. 
Immunofluorescence was performed as described in Materials and Methods. Localization of FPR2 and 
LAP2 was detected by incubating cells with α-FPR2 and α-LAP2 antibodies, respectively. Staining was 
performed by incubating cells with DAPI. Panel A, cells were transfected with empty vector. Panel B, 
cells were transfected with FPR2wt. Panel C, cells were transfected with FPR2mut3 (K230A). Panel D, 
cells were transfected with FPR2mutBis (H229A/K230A/K231A). Merge (yellow/orange) show co-
localization of DAPI, FPR2 and LAP2 (arrows). Cells showed no staining with secondary antibody alone. 
Data are representative of three independent experiments. 
 
Western blot analysis, performed on nuclear proteins purified from 
HEK293 cells transfected with the three constructs, was in agreement 
with immunofluorescence results. Cells transfected with FPR2wt 
showed nuclear localization of the receptor (Fig.19C, lane B), which 
was partially prevented when cells were transfected with FPR2mut3 
(Fig.19C, lane C). FPR2 nuclear localization was completely 
abolished in cells transfected with the triple mutant FPR2mutBis 
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(Fig.19C, lane D). Taken together these data indicate that H229 and 
K231 residues in the KIHKK sequence play a key role in the nuclear 
localization or translocation of FPR2. Accordingly, we did not 
observe nuclear expression of FPR1 and FPR3, where K231 is 
replaced by the polar aminoacids Q and N, respectively. 
 
 
Fig.19. FPR2 aminoacid sequence contains a NLS (C) Nuclear lysates were purified from HEK293 
cells transfected with empty vector (lane A), FPR2wt (lane B), FPR2mut3 (lane C) or FPR2mutBis (lane 
D). Proteins (30 μg) were resolved on 10% SDS-PAGE and FPR2 was detected by western blot with an 
α-Myc-tag antibody. α-YY1 was used as a marker for nuclear purity and as loading control. Relative 
expression was quantitatively estimated by densitometry using a Discover Pharmacia scanner equipped 
with a Sun Spark Classic densitometric workstation. *p<0.05 compared with cells transfected with the 
empty vector. The blots are representative of three separate experiments of identical design. 
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4. Discussion 
The results obtained during my Ph.D. show that the Formyl-
peptide Receptors are functionally expressed in several cell types 
unrelatedto polymorphonuclear compartment where they were initially 
identified. These receptors are promiscuous for the heterogeneity of 
intracellular signaling cascades activated, for their tissue specific 
expression or to the nature of theligands with which the receptors 
interact.  
We demonstrate that in serum-deprived PNT1A and ECV cells, 
stimulation of FPR2 by a specific agonist results in NADPH-oxidase-
dependent superoxide generation and RTKs transactivation. 
Furthermore, we show that ROS play a key role in bridging the signals 
from FPR2 to RTKs as demonstrated by the effects of apocynin, and a 
siRNA against p22phox on thetransactivation. Our results also 
indicate that, as a consequence of the trans-phosphorylation process 
the phosphotyrosine residues of RTKs provide docking sites for 
recruitmentand triggering of the STAT3 pathway. Several GPCRs can 
transactivate RTKs and the cross talk between the two classes of 
receptors is a crucial signaling mechanism that serves to expand the 
cellular communication network, thereby assisting the transmission of 
growth signals. In glioblastoma cells EGFR transactivation is 
mediated by the binding of N-fMLP to FPR1 and inhibition of EGFR 
phosphorylation significantly reduces FPR agonist-induced tumor cell 
chemotaxis and proliferation. Thus, FPR expressed in glioblastoma 
cells can exploit the EGFR capacity to amplify tumor growth [59]. A 
molecular mechanism that can contribute to RTKs transactivation by 
GPCR ligands is the generation of ROS, which in turn inactivate 
PTPases that tightly control the activity of RTK. In fact, oxidation and 
reduction of protein cysteine sulfhydryl groups of PTPases may act as 
a molecular switch to start or to stop signaling. Plasma membrane-
associated Nox enzymes catalyze the deliberate and regulated 
generation of ROS. In contrast to the cytotoxic amounts of superoxide 
generated by phagocytes, the non-phagocytic Nox family members are 
recognized as producers of low levels of ROS that play critical roles in 
maintaining normal physiologic processes and that stimulate 
intracellular signaling cascades via activation ofkinases and inhibition 
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of PTPases. Under physiological conditions, the intracellular 
production of ROS does not alter the redox state of cells, which have 
large reserves of reducing agents. This reducing intracellular 
environment allows agonist-induced increases in ROS to function as 
second messengers by limiting their effect in time and space. A major 
attribute of non-phagocytic NADPH oxidases is that not only are they 
constitutively active but their activity is sensitively influenced by a 
wide variety of (patho)physiological stimuli. Several pathological 
conditions are associated with overproduction of ROS by Nox 
enzymes. They include chronic diseases that tend to appear late in life, 
such as Alzheimer disease, atherosclerosis, hypertension, diabetic 
nephropathy, lung fibrosis, and cancer. In many of these diseases 
overproduction of ROS also results from increased expression of Nox 
enzymes and/or of their regulatory subunits [27]. 
STAT3 is a member of the STAT family of cytoplasmic transcription 
factors. It requires extrinsic tyrosine phosphorylation to become 
activated and this event is induced by RTKs, cytoplasmic c-Src 
tyrosine kinases, and components of the JAK family. Specific formyl 
peptide receptor agonists also activate STAT3. We found that in 
PNT1A and ECV cells exposure to agonists induces FPR1/2-
dependent phosphorylation of STAT3 at the Y705 and S727 
residues,suggesting that STAT3 activation is also a part of the 
FPR1/2-dependent signaling cascade. We also observed MEK-
dependent ERK phosphorylation in WKYMVm-stimulated cells. It 
hasbeen shown that the MAPK pathway plays an important role in the 
regulation of STAT3 signaling and that ERK are known to 
phosphorylate STAT3 at the S727 residue. FPR2 was initially known 
as a low-affinity receptor for N-fMLP. In the past few years several 
ligands have been identified, making FPR2 the most promiscuous in 
the FPR family with respect to agonist selectivity. Interestingly, most 
of the newly identified agonists for FPR2 do not share substantial 
sequence homology; thus, FPR2 behaves as a “pattern recognition” 
receptor that can be activated by a wide variety of unrelated ligands 
[16]. There have been ongoing efforts in several laboratories to study 
the ligand and FPR2 interaction, in part because of the potential for 
FPR2 to become a therapeutic target.It has been shown that both 
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agonists and antagonists for FPR2 have therapeutic value. In fact, 
WKYMVm increases neutrophil bactericidal activity in 
chemotherapy-treated cancer patients and enhances endogenous 
expression of TRAIL, a novel potential anticancer agent, in human 
monocytes and neutrophils. Moreover, the administration of 
WKYMVm protects against death by enhanced bactericidal activity 
and inhibition of vital organ inflammation and immune cell apoptosis 
in a cecal ligation and puncture sepsis mouse model. WKYMVm, 
activating FPR2, also potently inhibits HIV-1 Env-mediated fusion 
and viral infection through heterologous desensitization of the 
chemokine receptors CCR5 and CXCR4, suggesting a novel approach 
to the development of anti-HIV-1 reagents.The use of FPR2 by SAA, 
Aβ42, and human prion peptide suggests that this receptor may play a 
crucial role in proinflammatory aspects of systemic amyloidosis, 
Alzheimer disease, and prion diseases. This observation prompted 
studies in search of antagonists, which areimportant for delineating 
the signal transduction cascade associated with receptor activation and 
as a basis for developing anti-inflammatory therapeutic agents [21]. 
Several antagonists for FPR2 have been identified. These include the 
chemotaxis inhibitory protein of Staphylococcus aureus, the FPR2 
inhibitory protein FLIpr, the bile acids deoxycholic and 
chenodeoxycholic, and Quinc-7, a synthetic nonpeptide developed 
through chemical modification of Quinc-1[60]. Moreover, W-rich 
peptides, such as WRW4, exert an antagonistic effect on WKYMVm-
induced FPR2 signaling, suggesting their use for the treatment of 
several diseases in which FPR2 isknown to play a role. 
It should be also noted that because FPR is overexpressed in human 
glioblastoma cells, at least some members of the FPR family might 
also be valuable biomarkers for cancer diagnosis, therefore increasing 
the number of available biomarkers for cancer diagnosis and staging. 
The transactivation of RTKs by FPR2 in human cells may have 
important pathophysiological implications. The expression of FPR2 in 
these cells could render these cells responsivenot only to WKYMVm, 
but also to agonists contained in the environment of necrotic tumor 
cells. As a result of these interactions, FPR2 could activate 
intracellular signaling molecules such as ROS and ERKs that, in turn, 
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could trigger RTKs transactivation, the STAT3 pathway, and cell 
growth. This suggests that clarification of the resulting signaling 
cascades may open the way to new drugs that interfere with the FPR2 
signaling pathway and that targeting bothFPR2 and RTKs may yield 
superior therapeutic effects compared with targeting either receptor 
separately.  
The results also show for the first time that FPR2 localizes on the 
nuclear membrane of Calu-6 and AGS cells. Studies of intracellular 
trafficking of a few different GPCRs, evoked by exposure to ligand or 
by cellular activation through ligand-independent mechanisms, have 
shown that GPCRs may be inserted into nuclear membranes for 
prolonged periods. Nuclear GPCRs compose distinctive signaling 
units there, and respond to specific intracellular ligand by transducing 
nuclear transcriptional signals that differ from those sent by their 
plasma membrane complexes [39]. The physiological functions and 
mechanisms mediated by GPCRs on the nuclear membrane are not yet 
completely understood. A full complement of downstream signal 
trasduction components is present on the nuclear membrane including 
G proteins and enzyme effectors. Therefore, the resulting biological 
effects might result from the intregation of extracellular and 
intracellular signaling pathways. The nuclear (or perinuclear) 
localization can be attributed to translocation of a GPCR from the cell 
surface or de novo synthesis of the receptor. Nuclear GPCRs can be 
constitutively activated or activated by specific ligands. Further 
confirm of nuclear localization of GPCR  constitutively expressed, but 
also internalized in a ligand depend or indipendent manner, is 
supported by the recognition of a nuclear localization sequence (NLS). 
Searches in data bank revealed 17 GPCRs with a clearly recognizable 
NLS motif in the eighth helix including adenosine, angiotensin, 
bradykinin, and endothelin receptors. However, a putative NLS motif 
is located at the carboxyl-terminal region of the third intracellular loop 
in other receptors such as apelin receptor [50]. The nuclear 
distribution of FPR2 was assessed by western blot and 
immunofluorescence experiments using antibodies against the isoform 
of interst.Nuclear GPCRs might be derived from the cell membrane 
and their transfer to the nucleus can be attributed to a nuclear 
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localization motif which is recognized by members of the importin 
family, which act as carriers to transport the substrate protein across 
the nuclear pore [50]. The demonstration that FPR2 is expressed at the 
nuclear level raises questions about its function at this location. In 
general, nuclear-localized receptors may regulate distinct signaling 
pathways, suggesting that biological responses mediated by FPR2 are 
not only initiated at the cell surface but might result from the 
integration of extracellular and intracellular signaling pathways. 
Therefore, an important focus is to target single pathways associated 
with a plasma membrane or nuclear GPCR. This pathway-selective 
strategy might be based on targeting the assembly or trafficking of 
signaling complexes to distinct subcellular destinations through biased 
ligands, thus providing a selective set of discriminatory modulators. 
Pharmaceutical retention of FPR2 at the plasma membrane could be a 
novel strategy for inhibiting nuclear activities of FPR2 in pathological 
processes that involve this receptor. The access of ligands to nuclear 
receptors is another open question. Such ligands must be 
biosynthesized inside the cells or to cross the cellular membrane. 
FPR2 agonists that do not permeate cells have access only to receptors 
expressed on the plasma membrane. This observation provides a new 
concept for bioavailability of a drug, which should be defined also in 
terms of access of an agonist to intracellular domains of a receptor, 
and not only in the current terms of systemic absorption and tissue 
distribution. Taken together, our data indicate that FPRs play new 
unexepected roles in cell signaling and function. The promiscuity of 
these receptors in binding different ligands, coupled with their 
presence in different cells and tissues, indicates a diverse role in 
multiple biological settings. A better understanding of these 
fundamental functions could lead to the identification of new 
therapeutic targets for drug development. 
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a b s t r a c t
Cross-communication between GPCRs and TKRs represents a mechanism to amplify the information
exchange throughout the cell. We show that WKYMVm, an FPR2 agonist, induces the phosphoryla-
tion of Y1313/Y1349/Y1356 residues of c-Met and triggers some of the molecular responses elicited
by c-Met/HGF binding, such as STAT3, PLC-c1/PKCa and PI3K/Akt pathways. The critical role of
NADPH oxidase-dependent superoxide generation in this cross-talk mechanism is supported by
the ﬁnding that blockade of NADPH oxidase function prevents c-Met trans-phosphorylation and
the downstream signalling cascade. These results highlight the function of FPR2 to activate a inter-
connected signalling network and suggest novel possibilities for therapeutic interventions.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
1. Introduction
Eukaryotic cells have developed highly efﬁcient mechanisms of
receptor-mediated cell communication to coordinate and integrate
extracellular signals. The formyl-peptide receptors FPR1, FPR2 and
FPR3 belong to the G protein-coupled receptors (GPCR) super-fam-
ily and are coupled to pertussis toxin (PTX)-sensitive Gi proteins
[1]. FPR1 is efﬁciently activated by N-formyl-methionyl-leucyl-
phenylalanine, whereas FPR2 shows an higher binding efﬁciency
for WKYMVm [2]. The expression of these receptors has been dem-
onstrated in several cell types [3] and their important biological
functions are supported by the identiﬁcation of high afﬁnity
host-derived agonists. [4–6].
Despite GPCRs lack intrinsic tyrosine kinase activity, tyrosine
phosphorylation of a tyrosine kinase receptor (TKR) occurs in re-
sponse to binding of speciﬁc agonists of several such receptors.
GPCR ligands increase tyrosine phosphorylation of TKRs either by
increasing the kinase activity or by inhibiting an associated protein
tyrosine phosphatase [7]. These events are mediated by reactive
oxygen species (ROS) whose concentration increases transiently
in cells stimulated with GPCR agonists. Several evidence support
the role of ROS in TKR transactivation. For instance, in human lung
cancer cells stimulation of FPR2 by WKYMVm induces ROS-depen-
dent EGFR tyrosine phosphorylation [8] and in human carcinoma
cells ROS mediate c-Met transactivation by GPCRs [9]. The deliber-
ated and regulated generation of ROS is catalyzed by enzymes that
belong to NADPH oxidase (Nox) family, constituted by membrane
and cytosolic components. Phosphorylation of the regulatory cyto-
solic protein p47phox on several serine residues is associated with
oxidase activation [10].
The c-Met tyrosine kinase receptor (c-Met) is a cell surface
receptor for hepatocyte growth factor (HGF) [11]. Following HGF
binding, the tyrosine kinase domain of c-Met undergoes trans-
phosphorylation on the Y1234 and Y1235 residues in the activa-
tion loop [12]. Kinase activation by autophosphorylation leads to
the subsequent phosphorylation of Y1349 and Y1356 residues in
the C-terminal multifunctional docking site, resulting in the activa-
tion of c-Met signalling [12]. Previously, we demonstrated that
PNT1A cells express a functional c-Met and cell exposure to NK1,
a splice variant of HGF, induces the phosphorylation of Y1313/
Y1349/Y1356 residues of c-Met which provide docking sites for
the activation of intracellular signalling pathways [13].
The aims of this study were to analyze the cross-talk between
FPR2 and c-Met in PNT1A cells and to identify intracellular signal-
ling cascades triggered by the WKYMVM-mediated activation of
HGF receptor. We show that stimulation of FPR2 by its agonist re-
sults in the phosphorylation of tyrosine 1313/1349/1356 residues
of c-Met and promotes some of the molecular responses elicited
by the binding of HGF to its receptor.
0014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
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Abstract: The formyl peptide receptor 2 (FPR2) is a remarkably versatile transmembrane 
protein belonging to the G-protein coupled receptor (GPCR) family. FPR2 is activated by 
an array of ligands, which include structurally unrelated lipids and peptide/proteins 
agonists, resulting in different intracellular responses in a ligand-specific fashion. In 
addition to the anti-inflammatory lipid, lipoxin A4, several other endogenous agonists also 
bind FPR2, including serum amyloid A, glucocorticoid-induced annexin 1, urokinase and 
its receptor, suggesting that the activation of FPR2 may result in potent pro- or  
anti-inflammatory responses. Other endogenous ligands, also present in biological samples, 
include resolvins, amyloidogenic proteins, such as beta amyloid (Aβ)-42 and prion protein 
(Prp)106–126, the neuroprotective peptide, humanin, antibacterial peptides, annexin 1-derived 
peptides, chemokine variants, the neuropeptides, vasoactive intestinal peptide (VIP) and 
pituitary adenylate cyclase activating polypeptide (PACAP)-27, and mitochondrial 
peptides. Upon activation, intracellular domains of FPR2 mediate signaling to G-proteins, 
which trigger several agonist-dependent signal transduction pathways, including activation 
of phospholipase C (PLC), protein kinase C (PKC) isoforms, the phosphoinositide 3-kinase 
(PI3K)/protein kinase B (Akt) pathway, the mitogen-activated protein kinase (MAPK) 
pathway, p38MAPK, as well as the phosphorylation of cytosolic tyrosine kinases, tyrosine 
kinase receptor transactivation, phosphorylation and nuclear translocation of regulatory 
transcriptional factors, release of calcium and production of oxidants. FPR2 is an attractive 
therapeutic target, because of its involvement in a range of normal physiological processes 
and pathological diseases. Here, we review and discuss the most significant findings on the  
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Abstract: G protein-coupled receptors (GPCRs) are seven transmembrane-spanning proteins 
belonging to a large family of cell-surface receptors involved in many intracellular signaling 
cascades. Despite GPCRs lack intrinsic tyrosine kinase activity, tyrosine phosphorylation  
of a tyrosine kinase receptor (RTK) occurs in response to binding of specific agonists of several 
such receptors, triggering intracellular mitogenic cascades. This suggests that the notion that 
GPCRs are associated with the regulation of post-mitotic cell functions is no longer believable. 
Crosstalk between GPCR and RTK may occur by different molecular mechanism such  
as the activation of metalloproteases, which can induce the metalloprotease-dependent release  
of RTK ligands, or in a ligand-independent manner involving membrane associated non-receptor 
tyrosine kinases, such as c-Src. Reactive oxygen species (ROS) are also implicated as signaling 
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Abstract. Background/Aim: Formyl-peptide receptors (FPRs)
are expressed in several tissues and cell types. The
identification of markers involved in cell growth may further
allow for molecular profiling of lung cancer. We investigated
the possible role of FPRs as molecular markers in several types
of lung carcinomas which is the main cause of cancer death
worldwide. Materials and Methods: Tumor tissue samples were
collected from six patients affected by lung cancer. Biopsies
were analyzed for expression of FPR isoforms both in tumoral
and peritumoral tissue by real-time polymerase chain reaction
(PCR), western blot and immunofluorescence. Results: Real-
time PCR, western blot and immunofluorescence analyses
showed that FPR expression is lower in types of human lung
cancer tissues when compared to the surrounding peritumoral
tissues. Conclusion: The study of the mechanistic basis for the
control of FPR expression in normal peritumoral versus
tumoral tissues could provide the basis for new diagnostic and
therapeutic interventions. 
The human formyl-peptide receptors FPR1, FPR2 and FPR3
belong to the G-protein-coupled receptor (GPCR) family (1)
and were first detected in phagocytic leukocytes and in
monocytes. Their expression has also been demonstrated in
several tissues and cell types at the protein or mRNA levels
(2, 3) and their relevant biological functions have emerged
through identification of high affinity host-derived agonists.
Such ligands trigger intracellular signaling cascades
involving phosphatidylinositol 3-kinase, protein kinase C,
mitogen-activated protein kinases, signal transducer and
activator of transcription, cellular Src kinase, as well as
several transcription factors (4-6). 
Despite FPRs lack of intrinsic tyrosine kinase activity,
tyrosine phosphorylation of a tyrosine kinase receptor (RTK)
occurs in response to binding of agonists to such receptors,
triggering mitogenic pathways. FPR-mediated RTK
transactivation may occur by different molecular mechanisms,
which include the activation of metalloproteases or the
activation of membrane associated non-receptor tyrosine
kinases (7). Further evidence supports the role of reactive
oxygen species (ROS) in FPR-mediated RTK transactivation.
For instance, in human lung cancer cells, FPR2 stimulation
induces ROS-dependent Epidermal growth factor receptor
(EGFR) tyrosine phosphorylation (8) and in human prostate
cells, ROS mediate hepatocyte growth factor receptor
transactivation by FPR2 (9).
Lung cancer remains the leading cause of cancer-related
death worldwide. Tobacco smoking and air pollution
exposure are mainly implicated in lung cancer development
(10-13). Cytotoxic chemotherapy offers modest prolongation
in survival, although the additional gain in terms of response
rate and survival with combinations of chemotherapy and
monoclonal antibodies have reached a plateau (14-16). The
development of molecular profiling technologies to assess
DNA, RNA, protein and metabolites have provided
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